Positive Readouts, High Bar: Why the Market Faded GPCR
Phase 3 is years away, GI side effects appeared at active amylin doses, and the oral GLP-1 bar is already high.
Phase 3 is years away, GI side effects appeared at active amylin doses, and the oral GLP-1 bar is already high.
Novo Nordisk stopped the HERMES and ATHENA trials of ziltivekimab after a data committee said they were unlikely to succeed, following the ZEUS miss.
Analysts cite ziltivekimab’s trial miss, modest Medicare upside and patent risks.
Novo Nordisk faces tougher H2. Berenberg downgrades to Hold on rising rivalry with Lilly’s Foundayo.
Eli Lilly beats Q2 estimates with revenue up 48% to $23B, driven by Mounjaro and Zepbound. Company raises full-year outlook to $85–87 billion.
Despite Q2 beat and raise, Novo shares dropped on flat 2026 outlook, DKK 6.3B impairment, ZEUS failure and fierce Lilly competition.